908 Devices Inc. (NASDAQ:MASS) Q4 2023 Earnings Call Transcript

From a distribution of customers, if I look back at our desktop sales over the 2022 and 2023, the bulk of it is into the biopharma biotech customer space. We have less penetration in the academics, government and CDMO, CRO space. So I would say we’ve got about 50% to 70% in that biopharma biotech space and maybe only 15%, 20% in the academics. And where we have seen some increases would be really more in the life science suppliers, media providers, and importantly, some of the things we touched on, the Sartorius relationship, the innovators in bioprocessing equipment for biologics and cell and gene. So as we become part of other systems or do more of these partnerships, likely that will continue.

Steven Mah: Okay, thank you.

Operator: [Operator Instructions] And we have no further questions on the call, so I will hand the floor back to Kevin to wrap up.

Kevin Knopp: All right. Well, thank you all for your time and we appreciate you tuning in today and look forward to giving you further updates as we progress across 2024. Thank you.

Operator: This concludes today’s conference call. Thank you all very much for joining. You may now disconnect your lines.